Knowledge Check

Exam-style MCQs aligned with these notes. Available to Hyperexcision Scholar members.

Log in to access
Last updated: August 24, 2026Bookmark

Liver cirrhosis is irreversible liver damage that is characterised by diffuse bridging fibrosis and regenerative nodules. It has various causes, all of which lead to inflammation and damage to hepatocytes. Fibrosis causes increased resistance to blood flow in the liver, which leads to portal hypertension.

The overall 5-year survival for cirrhosis is 50%.

Differentials for portal hypertension

CategoryDifferentials
Pre-hepatic (portal vein)Portal vein thrombosis, structural abnormality of the portal vein (atresia or stenosis)
Intrahepatic (sinusoidal or parenchymal)Cirrhosis, PBC (even in the abscence of cirrhosis), nodular regenerative hyperplasia, schistosomiasis, massie fatty change, sarcoidosis, infiltrative malignancy, amyloidosis
Post-hepatic (hepatic veins and beyond)Right heart failure, budd-chiari syndrome, constrictive pericarditis
Stigmata of liver failure
  • Causes
    • Chronic alcohol abuse (most common cause)
    • Non-alcoholic steatohepatitis (NSAH)
    • Infectious disease
      • Chronic Hepatitis B and Hepatitis C (post-necrotic cirrhosis)
      • Schistosomiasis
    • Genetic disorders
      • Haemochromatosis
      • Alpha-1 antitrypsin deficiency
      • Wilson’s disease
      • Cystic fibrosis
    • Vascular disease
      • Budd-chiari syndrome
    • Autoimmune disease
      • Primary biliary cholangitis (PBC)
      • Autoimmune hepatitis
      • Primary sclerosing cholangitis
    • Drugs
    • Cryptogenic cirrhosis
  • Pathophysiology
    • Chronic liver injury → activation of hepatic stellate cells → fibrosis → impaired sinusoidal blood flow → portal hypertension and reduced hepatocellular function
    • Splanchnic vasodilatation and portal hypertension → portosystemic collaterals, splenomegaly, and ascites
    • Loss of functional hepatocytes:
      • Hypoalbuminaemia
      • Coagulopathy
      • Reduced detoxification
      • Cholestasis
      • Impaired immune surveilance → increased susceptibility to infections
  • Signs and symptoms
    • Cachexia
    • Jaundice
    • Hepatomegaly
    • Small nodular liver in advanced cirrhosis
    • Splenomegaly due to portal hypertension
    • Spider naevi
    • Leukonychia (associated with hypoalbuminaemia)
    • Terry’s nails (white proximal but red distal 1/3 reddened by telangiectasia)
    • Palmar erythema
    • Dupuytren contracture
    • Gynaecomastia and testicular atrophy
    • Bruising
    • Excoriation due to itching
    • Ascites
    • Caput medusae
    • Asterixis in decompensated liver disease
  • Investigations
    • Liver function tests
      • Normal or elevated bilirubin
      • Raised AST
      • Raised ALT
      • Raised ALP
      • Raised GGT
      • Low albumin (loss of synthetic function, late finding)
      • Raised PT/INR (loss of synthetic function, late finding)
    • Complete blood count
      • Leukopaenia and Thrombocytopaenia in hypersplenism
    • UECs: Urea and creatinine are often abnormally low in patients with liver disease which can make eGFR values appear more than they are
      • Urea and creatining be deranged in hepatorenal syndrome
    • Abdominal ultrasound can also be used to screen for hepatocellular carcinoma
      • Small liver or hepatomegaly
      • Nodular surface
      • Corkscrew appearance of hepatic arteries with increased flow (due to compensation to reduce portal flow)
      • Enlarged portal vein with reduced or reversed flow
      • Splenomegaly
      • Hepatic vein thrombus
      • Ascites
    • Ascitic tap for MCS and SAAG
      • Neutrophils > 250/mm3 indicates SBP
    • Hepatitis B and C serology to rule out chronic Hepatitis B and C
    • Autoantibodies to rule out autoimmune hepatitis, PBC and PSC
      • Antinuclear antibodies (ANA)
      • Smooth muscle antibodies (SMA)
      • Antimitochondrial antibodies (AMA)
      • Antibodies to liver kidney micorsome type-1 (LKM-1)
    • Ceruloplasmin to rule out wilson disease
    • Alpha-1 antitrypsin levels to rule out alpha-1 antitrypsin deficiency
    • Ferritin and transferrin saturation to rule out hereditary hemochromatosis
    • Alpha-fetoprotein every 6 months to screen for hepatocellular carcinoma
    • Enhanced liver fibrosis (ELF) is the first-line test for assessing fibrosis due to non-alcoholic fatty liver disease. It measuress HA, PIIINP and TIMP-1, and uses an algorithm to detect advanced fibrosis Measured q 3 years in NAFLD
      • ≥ 10.51 = advanced fibrosis
      • < 10.51 = unlikely advanced fibrosis
    • Transient elastography to ****assess the stiffness of the liver in order to determine the degree of fibrosis in patients at risk of cirrhosis
    • Endoscopy to asses for and treat oesophageal varices if portal hypertension is suspected
    • CT and MRI to look for hepatocellular carcinoma, hepatosplenomegaly, vascular pathology and ascites
    • Liver biopsy to confirm the diagnosis
      • Bridging fibrosis: Links portal tracts to each other and to central veins
      • Parenchymal (Regenerative nodules): result from regenerating hepatocytes surrounded by fibrosis. Lack normal liver architecture, lack portal triad and sinusoids and are surrounded by bands of fibrosis.
      • Disrupted hepatic parenchymal architecture
  • Common laboratory abnormalities seen in liver cirrhosis
    • Decreased serum BUN and increased serum Ammonia due to isruption of the urea cycle
    • Fasting hypoglycemia due to defective gluconeogenesis and decreased glycogen stores
    • Chronic respiratory alkalosis due to toxic products from hepatic dysfunction overstimulate respiratory centers
    • Lactic acidosis since the liver is unable to convert lactic acid to pyruvate
    • Hyponatremia
    • Hypokalemia secondary to hyperaldoesteronism which facilitates the K+ excretion in the renal tubules
    • Elevated PT due to decreaed synthesis of coagulation factors
    • Hypoalbuminemia due to decreased functional hepatocytes
    • Hypocalcemia
    • Decreaed total serum calcium secondary to hypoalbuminemia
    • Vitamin D deficiency
  • Treatment
    • Nutritional suppot
    • Abstain from alcohol
    • Avoid NSAIDs, sedatives and opioids
    • Cholestyramine for prurius
    • Ultrasound and a-fetoprotein to 6 months to screen for hepatocellular carcinoma
    • Liver transplant
    • Monitor and treat complications
  • Factors for poor prognosis
    • Encephalopathy
    • Hyponatremia < 110 mmol/L
    • Hypoalbuminaemia < 25 g/L
    • Raised INR

Complications of Cirrhosis

ComplicationDescription
Hepatic failureCoagulopathy, encephalopathy, hypoalbuminaemia (oedema), sepsis (pneumonia and sepicaeima), spontaneous bacterial peritonitis (SBP), hypoglycaemia,
Portal hypertensionAscites, splenomegaly, oesophageal varices (+/- life-threatening UGIB), caput medusae, hemorrhoids
Renal failureIgA nephropathy +/- hepatic glomerulosclerosis (due to reduced hepatic clearance of immune complexes), Hepatorenal syndrome
Hepatorenal syndromeIntense renal vasocontriction leading to renal dysfunction
Hepatopulmonary syndromeIntrapulmonary vascular dilation leading to V-Q mismatch and hypoxia. The patient may present with platypnoea
Portopulmonary hypertensionInadequate clearance of endothelin-1 causes excessive pulmonary vasoconstriction and vascular remodelling leading to pulmonary hypertension
Hyperestrinism in menDue to reduced degradation of estrogen and 17-ketosteroids (androstenedione – which is aromatized into estrogen) Gynaecomastia, spider telangiectasia, female distribution of hair, impotence and erectile dysfunction.
Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Leave a Reply

A moment of your time
Step 1 of 2

You are the reason this exists. Got 60 seconds? Help us improve Hyperexcision for every medical student who uses it.

The Hyperexcision Team